“…Rb1, Rg1, Rg2, Rg3, Rg5, Rd, Re, Rh1, 25-OCH 3 -PPD, and compound K (CK) in Panax ginseng inhibit NLRP3 inflammasome stimulation, leading to suppressed inflammatory responses and multiple disease conditions, such as obesity, gouty arthritis, atherosclerosis , non-alcoholic fatty liver disease, liver injury, hyperlipidemia, type I diabetes, myocardial hypertrophy and dysfunction, cerebral ischemia and reperfusion injury, colitis, hepatic fibrosis, sepsis, neuronal damage, kidney injury, and cognitive deficits [ [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] ]. Korean red ginseng (KRG) extract and KRG saponin fraction in Panax ginseng also inhibited inflammatory responses by inhibiting NLRP3 inflammasome activation in macrophages, monocytes, sepsis mice, and aging mice [ 65 , 74 ]. Chikusetsu saponin IVa, a major active triterpenoid saponin in Panax japonicus , inhibited NLRP3 inflammasome activation, hence ameliorating obesity and neuroinflammation in macrophages, adipocytes, primary neurons, and postoperative cognitive dysfunction rats [ 75 , 76 ].…”